| __timestamp | Blueprint Medicines Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 10811000 |
| Thursday, January 1, 2015 | 14456000 | 33001000 |
| Friday, January 1, 2016 | 19218000 | 64936000 |
| Sunday, January 1, 2017 | 27986000 | 99909000 |
| Monday, January 1, 2018 | 47928000 | 127724000 |
| Tuesday, January 1, 2019 | 96388000 | 161524000 |
| Wednesday, January 1, 2020 | 157743000 | 182933000 |
| Friday, January 1, 2021 | 195293000 | 219982000 |
| Saturday, January 1, 2022 | 237374000 | 278139000 |
| Sunday, January 1, 2023 | 295141000 | 309799000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, starting from a modest $7.89 million to nearly $295 million. Meanwhile, Ultragenyx's SG&A expenses grew by approximately 2,800%, reaching around $310 million in 2023 from $10.81 million in 2014.
This rapid escalation in spending reflects the companies' aggressive strategies to expand their market presence and invest in operational capabilities. Notably, both companies have consistently increased their SG&A budgets, with Ultragenyx maintaining a slightly higher expenditure than Blueprint Medicines in recent years. These trends underscore the dynamic nature of the biotech industry, where strategic spending is pivotal for growth and innovation.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
R&D Spending Showdown: Blueprint Medicines Corporation vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Blueprint Medicines Corporation or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Soleno Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared